Publication details
Lucentis v léčbě věkem podmíněné makulární degenerace
| Title in English | Lucentis in treatment of age related macular degeneration |
|---|---|
| Authors | |
| Year of publication | 2009 |
| Type | Article in Proceedings |
| Conference | Sborník 5. bilaterálního Česko-Slovenského oftalmologického sympózia |
| MU Faculty or unit | |
| Citation | |
| Field | ORL, ophthalmology, stomatology |
| Keywords | age related macular degeneration; choroidal neovascular membrane; vascular endothelial growth factor; ranibizumab |
| Description | The authors evaluated results achieved with the use of ranibizumab (Lucentis) for wet age-related macular degeneration (AMD). Ranibizumab (Lucentis, Novartis) is an antagonist of vascular growth factor (VEGF), approved for intraocular injection in the wet form of age-related macular degeneration (AMD). Ranibizumab in our department is used to treat patients with occult, minimally classic or predominantly classic subretinal neovascular membrane (CNV) in the subfoveal location. Patients included in the study had 3 applications ranibizumab every 1 month (loading phase), followed by applications as needed - the maintenance phase (ie, if a decrease visual acuity by more than 5 ETDRS letters, or edema will increase by more than 100 mi). Our 9-month results demonstrate the ability of Lucentis to stop the progression of wet AMD and preserve visual acuity in most patients. Improvement of visual acuity is possible in particular by the treatment of patients in earlier stages of disease. To maintain profit visual acuity to be a monthly monitored during the maintenance phase of treatment. |